The Aegis

Upper Chesapeake Health, UM Medical System reach monoclonal antibody treatment milestone

Thank you for supporting our journalism. This article is available exclusively for our subscribers, who help fund our work at The Baltimore Sun.

University of Maryland Upper Chesapeake Health recently administered the 5,000th monoclonal antibody treatment for COVID-19 in the University of Maryland Medical System, according to a news release.

A monoclonal infusion center was opened in February on the UM Upper Chesapeake Medical Center campus in Bel Air and has administered the second-most number of monoclonal antibody treatments across UMMS, providing more than 540 infusions, according the release.


Monoclonal antibody treatments are given to patients with mild-to-moderate COVID-19 who are at high risk for serious illness. If given within 10 days of symptom onset, monoclonal antibody treatments have demonstrated the ability to reduce progression of severe COVID-19 and the need for hospitalization.

The 5,000th systemwide treatment was administered to Dr. Edward Arrison, an anesthesiologist who is a Havre de Grace resident, according to the release. He was fully vaccinated but ended up catching COVID-19. Arrison was part of the original Pfizer COVID-19 vaccine clinical trial, which began about a year ago through Pharmaron.


When Dr. Arrison wasn’t feeling well and after he tested positive for COVID-19, he reached out to his primary care provider, who referred him to the mAb clinic at UM UCH about receiving the monoclonal antibody therapy.

“I am thankful that I had this option to come and get this procedure done. It was totally painless, took about a half-hour and I feel great,” Arrison said in the release.

Mary Ghaffari, Director of UMMS Clinical Pharmacy Services, explained, “A monoclonal antibody is an immune protein that is manufactured in a laboratory by the pharmaceutical companies and is designed to bind to a specific receptor in the body to help prevent worsening of symptoms and decreases the risk of hospitalization and death.”

While not a substitute for vaccination, monoclonal antibody therapies have been used to treat diseases such as cancer and autoimmune disorders since the mid-1990s, according to the release.